Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 3/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27747 | 0.90 | MMP8 (0.58) | MMP8MAPK1MEN1S1PR4LMNA | |
| SCHEMBL9710075 | 0.88 | MMP8 (0.50) | MMP8MAPK1MEN1S1PR4LMNA | |
| SCHEMBL6421966 | 0.87 | MME (0.45) | MEN1KMT2AMMESMN1; SMN2LDHA | |
| SCHEMBL2426124 | 0.86 | MMP8 (0.54) | MMP8MAPK1MEN1S1PR4LMNA | |
| SCHEMBL534033 | 0.84 | EPHX2 (0.49) | MMP8MEN1LMNAMAPTKMT2A | |
| SCHEMBL3784871 | 0.84 | PPARG (0.49) | MMP8MAPK1MEN1LMNAMAPT | |
| SCHEMBL2570738 | 0.83 | LDHA (0.61) | MMP8MAPK1MEN1LMNAMAPT | |
| SCHEMBL534859 | 0.83 | ALDH1A1 (0.48) | MMP8LMNAKMT2AALDH1A1TP53 | |
| SCHEMBL11458354 | 0.82 | MME (0.42) | MEN1KMT2AMMESMN1; SMN2LDHA | |
| SCHEMBL1312803 | 0.81 | MMP8 (0.62) | MMP8MAPK1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394830-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| CN-101679359-B | Quinolines and their therapeutic use | ARGENTA DISCOVERY LTD | 2013-03-06 | — | — | CN | disclosed |
| US-20120184579-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2012-07-19 | — | — | US | disclosed |
| US-8173812-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| EP-2129661-B1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2012-02-08 | — | — | EP | disclosed |
| EP-2139881-B1 | QUINOLINES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2011-11-09 | — | — | EP | disclosed |
| US-20100144787-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100144786-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| CN-101715441-A | Quinoline derivatives as CRTH2 receptor ligands | ARGENTA DISCOVERY LTD | 2010-05-26 | — | — | CN | disclosed |
| CN-101679359-A | Quinolines and their therapeutic use | ARGENTA DISCOVERY LTD | 2010-03-24 | — | — | CN | disclosed |
| EP-2139881-A1 | QUINOLINES AND THEIR THERAPEUTIC USE | Argenta Oral Therapeutics Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| EP-2129661-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | Argenta Oral Therapeutics Limited (GB) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008122784-A1 | QUINOLINES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008119917-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | ARGENTA DISCOVERY LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144786-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | NR1H2, GPR52, HRH2 | MMP8 2193/4885MAPK1 1895/4885MEN1 4563/4885 |
| US-20100144787-A1 | Quinolines and Their Therapeutic Use | CHRM3, CHRM2, HRH1 | MMP8 2397/4885MAPK1 1936/4885MEN1 2947/4885 |
| US-20120184579-A1 | Quinolines and Their Therapeutic Use | HRH1, CHRM2, CHRM3 | MMP8 2720/4885MAPK1 2045/4885MEN1 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.